organization · Reporting owner

Decheng Capital Management IV (Cayman), LLC

Disclosed activity across 3 companies

Tapewire entity: 83057
SEC CIK: 0001843384

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aardvark Therapeutics, Inc.AARD · Entity 6598	10% owner	February 14, 2025	February 19, 2025
Equillium, Inc.EQ · Entity 6560	10% owner	February 05, 2021	February 16, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aardvark Therapeutics, Inc.

Report date February 14, 2025 · Filed February 19, 2025

Jointly reported with Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Decheng Capital Global Life Sciences Fund IV, L.P.	2,958,887	Last balance in matching sequence After 2025-02-14 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2025-02-14 · Conversion · Acquired 2,333,887 · Balance 2,333,887 F1: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F2: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Row 3 · 2025-02-14 · Purchase · Acquired 625,000 · Balance 2,958,887 F2: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Decheng Capital Global Healthcare Fund (Master), LP	958,412	Last balance in matching sequence After 2025-02-14 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2025-02-14 · Conversion · Acquired 333,412 · Balance 333,412 F1: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F3: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Row 4 · 2025-02-14 · Purchase · Acquired 625,000 · Balance 958,412 F3: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Decheng Capital Global Life Sciences Fund IV, L.P.	0	Reported balance After 2025-02-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-02-14 · Conversion · Disposed 19,777,363 · Balance 0 F1: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F2: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectBy Decheng Capital Global Healthcare Fund (Master), LP	0	Reported balance After 2025-02-14 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-02-14 · Conversion · Disposed 2,825,337 · Balance 0 F1: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F3: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.

F2: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

F3: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Equillium, Inc.

Report date February 05, 2021 · Filed February 16, 2021

Jointly reported with Decheng Capital Global Life Sciences Fund IV, L.P., Cui Xiangmin

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,285,710	Reported balance Holding disclosure · report date 2021-02-05 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 3,285,710 F1: The reportable securities are included within 3,285,710 units representing (i) 3,285,710 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), and (ii) warrants to purchase an additional 985,713 shares of Common Stock for $7.00 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock). F2: The reportable securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (the "Fund"). Decheng Capital Management IV (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2026-02-05	IndirectSee Footnote	Not disclosed	Reported balance Holding disclosure · report date 2021-02-05 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: The reportable securities are included within 3,285,710 units representing (i) 3,285,710 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), and (ii) warrants to purchase an additional 985,713 shares of Common Stock for $7.00 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock). F2: The reportable securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (the "Fund"). Decheng Capital Management IV (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reportable securities are included within 3,285,710 units representing (i) 3,285,710 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), and (ii) warrants to purchase an additional 985,713 shares of Common Stock for $7.00 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock).

F2: The reportable securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (the "Fund"). Decheng Capital Management IV (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CG Oncology, Inc.

Report date January 29, 2024 · Filed April 09, 2024 · Amendment

Jointly reported with Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin

Section 16 reporting ended · disclosed 2024-04-09. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,958,810	Reported balance After 2024-01-29 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2024-01-29 · Purchase · Acquired 400,000 · Balance 4,958,810 F1: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 14, 2025 Filed Feb 19, 2025 22:44 UTC	Aardvark Therapeutics, Inc. AARD · Entity 6598	ConversionSeries C Convertible Preferred Stock · Derivative	2,825,337	$0.00	$0.00	Disclosure SEC source: 0000950170-25-023409 · ownership.xml · derivative · entry 6 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 0 Underlying: Common Stock · 333,412 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F3 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
February 14, 2025 Filed Feb 19, 2025 22:44 UTC	Aardvark Therapeutics, Inc. AARD · Entity 6598	ConversionSeries C Convertible Preferred Stock · Derivative	19,777,363	$0.00	$0.00	Disclosure SEC source: 0000950170-25-023409 · ownership.xml · derivative · entry 5 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Life Sciences Fund IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,333,887 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
February 14, 2025 Filed Feb 19, 2025 22:44 UTC	Aardvark Therapeutics, Inc. AARD · Entity 6598	PurchaseCommon Stock	625,000	$16.00	$10,000,000.00	Disclosure SEC source: 0000950170-25-023409 · ownership.xml · nonDerivative · entry 4 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 958,412 F3 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
February 14, 2025 Filed Feb 19, 2025 22:44 UTC	Aardvark Therapeutics, Inc. AARD · Entity 6598	PurchaseCommon Stock	625,000	$16.00	$10,000,000.00	Disclosure SEC source: 0000950170-25-023409 · ownership.xml · nonDerivative · entry 3 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Life Sciences Fund IV, L.P. Disclosed balance after: 2,958,887 F2 · ownership.nature: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
February 14, 2025 Filed Feb 19, 2025 22:44 UTC	Aardvark Therapeutics, Inc. AARD · Entity 6598	ConversionCommon Stock	333,412	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-023409 · ownership.xml · nonDerivative · entry 2 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 333,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F3 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
February 14, 2025 Filed Feb 19, 2025 22:44 UTC	Aardvark Therapeutics, Inc. AARD · Entity 6598	ConversionCommon Stock	2,333,887	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-023409 · ownership.xml · nonDerivative · entry 1 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Life Sciences Fund IV, L.P. Disclosed balance after: 2,333,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:17 UTC	CG Oncology, Inc. CGON · Entity 3735	ConversionSeries F Preferred Stock · Derivative	4,402,320	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-002062 · form4-01312024_090105.xml · derivative · entry 5 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 461,701 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:17 UTC	CG Oncology, Inc. CGON · Entity 3735	ConversionSeries E Preferred Stock · Derivative	21,547,685	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-002062 · form4-01312024_090105.xml · derivative · entry 4 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,259,851 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:17 UTC	CG Oncology, Inc. CGON · Entity 3735	ConversionSeries C Preferred Stock · Derivative	8,644,891	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-002062 · form4-01312024_090105.xml · derivative · entry 3 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 906,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:17 UTC	CG Oncology, Inc. CGON · Entity 3735	PurchaseCommon Stock	400,000	$19.00	$7,600,000.00	Disclosure SEC source: 0001415889-24-002062 · form4-01312024_090105.xml · nonDerivative · entry 2 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 400,000 F3 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
January 29, 2024 Filed Jan 31, 2024 21:17 UTC	CG Oncology, Inc. CGON · Entity 3735	ConversionCommon Stock	3,628,198	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-002062 · form4-01312024_090105.xml · nonDerivative · entry 1 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,558,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
January 29, 2024 Filed Apr 9, 2024 23:08 UTC Amendment	CG Oncology, Inc. CGON · Entity 3735	PurchaseCommon Stock	400,000	$19.00	$7,600,000.00	Disclosure SEC source: 0001415889-24-010609 · form4a-04092024_110416.xml · nonDerivative · entry 1 Decheng Capital Global Life Sciences Fund IV, L.P. · CIK 0001834150 · 10% owner Decheng Capital Management IV (Cayman), LLC · CIK 0001843384 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,958,810 F1 · ownership.direct: These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.